10.2337/dc17-0417
Menopause has also been suggested as a factor that increases the probability of maintaining normoprolactinemia after dopamine agonist therapy is stopped.18 Unless there is evidence of growth of a prolactinoma or related symptoms, such as headache, there is no indication to continue dopamine agonist therapy after menopause.18 There are no significant differences in age, sex, initial dopamine agonist dose or length of treatment between those with continued normoprolactinemia and those with recurrence of hyperprolactinemia.18 We suggest that the dopamine agonist dose be decreased after 2 or 3 years of normal prolactin levels and that therapy be stopped if the prolactin levels remain unchanged after 1 year at the reduced dose
This is due to various factors, including poor diets, malabsorption of vitamins, and certain medical conditions and medications which can contribute to lower levels of vitamin B12 in the body
Injection site reactions remain mild for both medications when proper technique is used
We customized packaging options, including branding and design, as per our clients demands and also complied with the packaging regulations and guidelines
J Endocrinol (1991) 130(2):26772